Trading statement here: |
Lots of companies doing well but billions is being yanked out of UK stocks thanks to these incompetents |
Solid trading statement. |
Berenberg raises Haleon price target to 454 (447) pence - 'buy' |
Haleon Investing £130m In Oral Health Innovation Centre |
UBS raises Haleon price target to 445 (410) pence - 'buy'
Deutsche Bank raises Haleon price target to 375 (340) pence - 'hold'
Barclays cuts Haleon price target to 406 (407) pence - 'overweight' |
Total volume traded 23 million shares. Quite a few unloading. |
Haleon down nearly 3%,maybe like GSK yanks have found something in their toothpaste ! |
Big volume , 9 million printed already. |
Plenty of profit to be taken.
Chartwise, support at 370p , then 347p if that doesn't hold. |
Glaxo is up though which takes the edge off it. |
Strong demand ?now 10p down how Strong you like! |
Yes indeed. Strong demand for those shares. |
Very well handled. |
(Alliance News) - Pfizer Inc sold a 7.6% stake in consumer health products firm Haleon PLC for GBP2.7 billion, the investment banks running the offer confirmed on Tuesday.
Pfizer, a New York-based pharmaceuticals firm, sold 640 million Haleon shares at 380 pence per share in a placing run by Goldman Sachs International and BofA Securities as joint global coordinators. Haleon bought back an additional 60.5 million shares from Pfizer at the same price.
As a result, Pfizer's stake in Haleon has been reduced to 15.0% from 22.6%. |
Pfizer's holding of HLN will now be down to appx 15% after these transactions. |
And HLN buying £230 million worth from Pfizer subject to completion of Pfizer's offering |
I see a large blocks of shares going under the hammer, good luck all |
On the FTSE 100, Haleon rose 0.4%.
The Weybridge, Surrey-based consumer healthcare firm said it will acquire an additional 33% equity interest in Tianjin TSKF Pharmaceutical Co Ltd, its JV in China, for a total of CNY4.47 billion or about GBP500 million.
The acquisition, subject to regulatory clearances, will see Haleon increase its stake to 88% from 55%.
Haleon highlights that TSKF accounted for about 40% of its China revenue in financial year 2023.
Alliance News |
The dividend is pathetic here. |
Indeed, a cracking run up since the end of June, further supported by the H1 financials and buyback, I was aiming to double down here in the ISA at 325 pence after the summer 2022 1:5 stock split but BATS offered up an income opportunity I could not refuse so it went there instead but will try again next year..
As the debt comes off here and we hit our target multiple of 2.5X debt/EBITDA dividends should accelerate.. :o) |
Yes they have. As you say HLN has shown high growth, in my case against my personal demerger tax base cost of about 249p. That figure will vary for everyone as it depends on their original cost of old GSK.
But as I've said I'm only in shares for the divis and as such have been running an income port for decades, not for capital gains, though the latter are of course welcome. I hold very long term in most cases and will definitely be retaining my HLN stock. |
#Anhar, they have done well have they not, 273-395 pence for me since July 2022 which makes up for the small dividend, but we should hit the 2.5X net debt/EBITDA leverage target this period and it could be the dividend steps up again.. :o) |
I'd add bid potential to the reasons for the high rating. There was already an abortive bid from Unilever just prior to the GSK demerger so I expect many people think that HLN may be taken out at some stage.
I retained my demerger HLN shares which have shown excellent growth, driving up the rating, though I'm just an income investor and it has demonstrated decent divi growth over its short independent existence. |
Register to chat with like-minded investors on our interactive forums.
Hot Features
Premium
